William L. Blalock

5.2k total citations · 2 hit papers
73 papers, 4.3k citations indexed

About

William L. Blalock is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, William L. Blalock has authored 73 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Molecular Biology, 16 papers in Oncology and 9 papers in Immunology. Recurrent topics in William L. Blalock's work include RNA regulation and disease (13 papers), Cytokine Signaling Pathways and Interactions (13 papers) and RNA Research and Splicing (11 papers). William L. Blalock is often cited by papers focused on RNA regulation and disease (13 papers), Cytokine Signaling Pathways and Interactions (13 papers) and RNA Research and Splicing (11 papers). William L. Blalock collaborates with scholars based in Italy, United States and Chile. William L. Blalock's co-authors include James A. McCubrey, Linda S. Steelman, Richard A. Franklin, Patrick M. Navolanic, Fuju Chang, J G Shelton, Alberto Bavelloni, Manuela Piazzi, Irene Faenza and Fumin Chang and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Cancer Research.

In The Last Decade

William L. Blalock

70 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy

2003 999 citations Linda S. Steelman, J G Shelton et al. Leukemia profile →
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention

2003 577 citations Linda S. Steelman, J G Shelton et al. Leukemia profile →

Peers

William L. Blalock

ONCOL

IMMUN

PFM

Jörg Bäsecke Germany

Joan Gil Spain

Kiyotsugu Yoshida Japan

Michael J. Ausserlechner Austria

Reid P. Bissonnette United States

Nancy Krett United States

Michael H. Cardone United States

Frank Eßmann Germany

Jeffrey A. Medin Canada

Peter P. Ruvolo United States

Jörg Bäsecke Germany

William L. Blalock

3.0k ×1.0

1.2k ×1.2

ONCOL

669 ×1.0

395 ×0.8

IMMUN

460 ×1.3

PFM

Citations per year, relative to William L. Blalock William L. Blalock (= 1×) peers Jörg Bäsecke

Countries citing papers authored by William L. Blalock

Since Specialization

Citations

This map shows the geographic impact of William L. Blalock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William L. Blalock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William L. Blalock more than expected).

Fields of papers citing papers by William L. Blalock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William L. Blalock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William L. Blalock. The network helps show where William L. Blalock may publish in the future.

Co-authorship network of co-authors of William L. Blalock

This figure shows the co-authorship network connecting the top 25 collaborators of William L. Blalock. A scholar is included among the top collaborators of William L. Blalock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William L. Blalock. William L. Blalock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Evangelisti, Camilla, Antonietta Fazio, William L. Blalock, et al.. (2025). Combining prelamin A accumulation and oxidative stress: A strategy to target glioblastoma. European Journal of Cell Biology. 104(2). 151491–151491.

Cenni, Vittoria, Alberto Bavelloni, Cristina Capanni, et al.. (2025). ANKRD2 Knockdown as a Therapeutic Strategy in Osteosarcoma: Effects on Proliferation and Drug Response in U2OS and HOS Cells. International Journal of Molecular Sciences. 26(4). 1736–1736.

Salucci, Sara, Alberto Bavelloni, Sabrina Burattini, et al.. (2024). Phospholipase Cδ-4 (PLCδ4) Acts as a Nuclear Player to Influence Cyclin B Expression in the Embryonal Rhabdomyosarcoma Cell Lines RD and A204. Biomolecules. 14(9). 1180–1180. 2 indexed citations

Piazzi, Manuela, Alberto Bavelloni, Sara Salucci, Irene Faenza, & William L. Blalock. (2023). Alternative Splicing, RNA Editing, and the Current Limits of Next Generation Sequencing. Genes. 14(7). 1386–1386. 9 indexed citations

Salucci, Sara, Beatrice Aramini, Anna Bartoletti‐Stella, et al.. (2023). Phospholipase Family Enzymes in Lung Cancer: Looking for Novel Therapeutic Approaches. Cancers. 15(12). 3245–3245. 5 indexed citations

Mancarella, Caterina, Maria Antonella Laginestra, Alessandro Parra, et al.. (2023). Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/Akt pathway in neighboring cells. Cancer Gene Therapy. 30(9). 1285–1295. 6 indexed citations

Salucci, Sara, Alberto Bavelloni, Francesco� Fabbri, et al.. (2023). The Cytotoxic Effect of Curcumin in Rhabdomyosarcoma Is Associated with the Modulation of AMPK, AKT/mTOR, STAT, and p53 Signaling. Nutrients. 15(3). 740–740. 12 indexed citations

Salucci, Sara, Anna Bartoletti‐Stella, Alberto Bavelloni, et al.. (2022). Extra Virgin Olive Oil (EVOO), a Mediterranean Diet Component, in the Management of Muscle Mass and Function Preservation. Nutrients. 14(17). 3567–3567. 20 indexed citations

Akula, Shaw M., Stephen L. Abrams, Linda S. Steelman, et al.. (2020). Cancer therapy and treatments during COVID-19 era. Advances in Biological Regulation. 77. 100739–100739. 33 indexed citations

10.

Piazzi, Manuela, Alberto Bavelloni, Angela Gallo, & William L. Blalock. (2020). AKT-Dependent Phosphorylation of ADAR1p110 and ADAR2 Represents a New and Important Link Between Cell Signaling and RNA Editing. DNA and Cell Biology. 39(3). 343–348. 7 indexed citations

11.

Ramazzotti, Giulia, Alberto Bavelloni, William L. Blalock, et al.. (2015). BMP‐2 Induced Expression of PLCβ1 That is a Positive Regulator of Osteoblast Differentiation. Journal of Cellular Physiology. 231(3). 623–629. 30 indexed citations

12.

Blalock, William L., Cecilia Grimaldi, Federica Falà, et al.. (2009). PKR activity is required for acute leukemic cell maintenance and growth: A role for PKR‐mediated phosphatase activity to regulate GSK‐3 phosphorylation. Journal of Cellular Physiology. 221(1). 232–241. 31 indexed citations

13.

Bennett, Richard L., William L. Blalock, Young Jae Lee, et al.. (2008). RAX is required for fly neuronal development and mouse embryogenesis. Mechanisms of Development. 125(9-10). 777–785. 25 indexed citations

14.

Falà, Federica, William L. Blalock, Pier Luigi Tazzari, et al.. (2008). Proapoptotic Activity and Chemosensitizing Effect of the Novel Akt Inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-Cell Acute Lymphoblastic Leukemia. Molecular Pharmacology. 74(3). 884–895. 27 indexed citations

15.

Martelli, Alberto M., Pier Luigi Tazzari, Camilla Evangelisti, et al.. (2007). Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Module for Acute Myelogenous Leukemia Therapy: From Bench to Bedside. Current Medicinal Chemistry. 14(19). 2009–2023. 101 indexed citations

16.

Bennett, Richard L., William L. Blalock, Sue A. Moyer, & W. Stratford May. (2006). Rax-dependent PKR activation is required for host anti-viral defense after vesicular stomatitis virus infection. Cancer Research. 66. 1044–1045. 1 indexed citations

17.

Shelton, J G, Linda S. Steelman, William L. Blalock, et al.. (2003). Differential effects of kinase cascade inhibitors on neoplastic and cytokine-mediated cell proliferation. Leukemia. 17(9). 1765–1782. 40 indexed citations

18.

McCubrey, James A., Linda S. Steelman, William L. Blalock, et al.. (2001). Synergistic effects of pi3k/akt on abrogation of cytokine-dependency induced by oncogenic raf. Advances in Enzyme Regulation. 41(1). 289–323. 20 indexed citations

19.

Blalock, William L., M Pearce, Linda S. Steelman, et al.. (2000). A conditionally-active form of MEK1 results in autocrine transformation of human and mouse hematopoietic cells. Oncogene. 19(4). 526–536. 68 indexed citations

20.

McCubrey, James A., LS Steelman, William L. Blalock, et al.. (1998). Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia. 12(12). 1903–1929. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact